Suzhou Porton Biologics Ltd, a China-based Contract Development and Manufacturing Organization (CDMO), has entered into a strategic partnership with Kunshi Biotechnology (Shenzhen) Co., Ltd. The collaboration aims to expedite the Investigational New Drug (IND) filing for Kunshi’s drug candidate RR-M01, marking a significant step forward in the development of third-generation chimeric antigen receptor macrophage (CAR-M) products. The financial terms of the agreement have not been disclosed.
RR-M01, a CAR-M drug, is positioned as a potential first-in-class global therapy. The first clinical subject has already been dosed and assessed, with positive results indicating the therapy’s potential efficacy and safety profile. This partnership is expected to leverage Suzhou Porton Biologics’ expertise in CDMO services to accelerate the progression of RR-M01 through the IND filing process and towards commercialization.
The alliance between Suzhou Porton Biologics and Kunshi Biotechnology underscores the dynamic growth in China’s biopharmaceutical sector, with companies increasingly partnering to drive innovation in cutting-edge therapies such as CAR-M products.- Flcube.com
